User profiles for Fei Tang

Fei Tang

- Verified email at va.gov - Cited by 885

Fei Tang, PharmD, PhD

- Verified email at gene.com - Cited by 533

Fei Tang

- Verified email at here.com - Cited by 280

Drug-resistant epilepsy: multiple hypotheses, few answers

F Tang, AMS Hartz, B Bauer - Frontiers in neurology, 2017 - frontiersin.org
Epilepsy is a common neurological disorder that affects over 70 million people worldwide.
Despite the recent introduction of new antiseizure drugs (ASDs), about one-third of patients …

Random forest missing data algorithms

F Tang, H Ishwaran - Statistical Analysis and Data Mining: The …, 2017 - Wiley Online Library
Random forest (RF) missing data algorithms are an attractive approach for imputing missing
data. They have the desirable properties of being able to handle mixed types of missing data…

Clinical features and outcomes of pregnant women suspected of coronavirus disease 2019

G Sun, F Tang, M Peng, Y Gao, J Peng, H Xie, Y Zhao… - Journal of infection, 2020 - Elsevier
Background 2019 novel coronavirus disease (COVID-19) has become a worldwide pandemic.
Under such circumstance pregnant women are also affected significantly. Objective This …

[HTML][HTML] COVID-19 immune features revealed by a large-scale single-cell transcriptome atlas

…, W Wen, X Fan, W Hou, B Su, P Cai, J Li, Y Liu, F Tang… - Cell, 2021 - cell.com
A dysfunctional immune response in coronavirus disease 2019 (COVID-19) patients is a
recurrent theme impacting symptoms and mortality, yet a detailed understanding of pertinent …

A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy

X Du, F Tang, M Liu, J Su, Y Zhang, W Wu… - Cell research, 2018 - nature.com
It is assumed that anti-CTLA-4 antibodies cause tumor rejection by blocking negative signaling
from B7-CTLA-4 interactions. Surprisingly, at concentrations considerably higher than …

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

F Tang, P Zheng - Cell & bioscience, 2018 - Springer
Antibody blockade of the PD-1/PD-L1 pathway has elicited durable antitumor responses in
the therapy of a broad spectrum of cancers. PD-L1 is constitutively expressed in certain …

A pan-cancer single-cell panorama of human natural killer cells

F Tang, J Li, L Qi, D Liu, Y Bo, S Qin, Y Miao, K Yu… - Cell, 2023 - cell.com
Natural killer (NK) cells play indispensable roles in innate immune responses against tumor
progression. To depict their phenotypic and functional diversities in the tumor …

Thrombin induces ACSL4-dependent ferroptosis during cerebral ischemia/reperfusion

…, T Zou, Y Shu, X Ding, J Zou, S Xu, F Tang… - Signal transduction and …, 2022 - nature.com
Ischemic stroke represents a significant danger to human beings, especially the elderly.
Interventions are only available to remove the clot, and the mechanism of neuronal death during …

Anti-CTLA-4 antibodies in cancer immunotherapy: selective depletion of intratumoral regulatory T cells or checkpoint blockade?

F Tang, X Du, M Liu, P Zheng, Y Liu - Cell & Bioscience, 2018 - Springer
Antibodies to human CTLA-4 have been shown to induce long-lasting protection against
melanoma. It is assumed that these antibodies cause tumor rejection by blocking negative …

Partially matched related donor transplantation can achieve outcomes comparable with unrelated donor transplantation for patients with hematologic malignancies

…, Z Xiao-Hui, S Hong-Xia, W Feng-Rong, T Fei-Fei - Clinical Cancer …, 2009 - AACR
Purpose: The study aimed to compare the outcomes of patients undergoing hematopoietic
stem cell transplantation (HSCT) from partially matched related donors (PMRD) and unrelated …